NCT06786312View on ClinicalTrials.gov

A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 25, 2025

Primary Completion Date

July 25, 2027

Study Completion Date

September 25, 2028

Conditions
Small Cell Lung Cancer Extensive Stage
Interventions
DRUG

Apatinib

250mg, P.O, qd, 21 days per cycle;

DRUG

Adebrelimab

20mg/kg or 1200mg ivgtt, d1, 21 days per cycle;

DRUG

Etoposide Injection

100mg/m\^2 ivgtt for the first, second and third consecutive days, 21 days per cycle.

DRUG

Carboplatin Injection

Day 1 administration, AUC=5, intravenous infusion; One treatment cycle every 21 days.

Trial Locations (4)

Unknown

Fujian Cancer Hospital, Fuzhou

Fujian Provincial Hospital, Fuzhou

The First Affiliated Hospital of Xiamen University, Xiamen

The First Affiliated Hospital of Fujian Medical University, Fuzhou

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV